AstraZeneca Stops Farxiga Trials Early Due to Overwhelming Efficacy
March 30 2020 - 2:53AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that trials for its diabetes drug
Farxiga in patients with chronic kidney disease were stopped early
based on its determination of overwhelming efficacy.
The FTSE 100-listed pharmaceutical company said the decision was
made following a routine assessment of efficacy and safety which
showed Farxiga's benefits earlier than originally anticipated. The
company said it will now initiate closure of the trial.
"Chronic kidney disease patients have limited treatment options,
particularly those without type-2 diabetes. We are very pleased the
Data Monitoring Committee concluded that patients experienced
overwhelming benefit," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
March 30, 2020 02:38 ET (06:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024